Dyne Therapeutics, Inc. (DYN)
NASDAQ:DYN
Want to see DYN full AI Analyst Report?
DYN Stock Chart & Stats
$20.41
-$0.74(-3.10%)
At close: 4:00 PM EST
$20.41
-$0.74(-3.10%)
Day’s Range― - ―
52-Week Range$8.06 - $25.00
Previous CloseN/A
Volume117.44K
Average Volume (3M)1.67M
Market Cap
$3.46B
Enterprise Value$2.44B
Total Cash (Recent Filing)$972.16M
Total Debt (Recent Filing)$19.30M
Price to Earnings (P/E)―
Beta1.75
Next Earnings
Jul 30, 2026EPS Estimate
-0.75Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.22
Shares Outstanding165,313,800
10 Day Avg. Volume2,116,307
30 Day Avg. Volume1,666,035
Financial Highlights & Ratios
PEG Ratio-1.90
Price to Book (P/B)2.58
Price to Sales (P/S)0.00
P/FCF Ratio-6.20
Enterprise Value/Market Cap0.70
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-2.28K
Enterprise Value/Ebitda-5.65
Forecast
1Y Price Target
$39.00Price Target Upside91.08% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)-3.08
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Platform & Focused Neuromuscular PipelineDyne’s FORCE™ delivery platform is a durable competitive asset for therapies targeting muscle tissue. A platform that can enable multiple antisense or payload programs increases program optionality and long-term value capture across rare neuromuscular indications, reducing single-program binary risk.
Clinical Execution And Registrational ProgressFull enrollment at a registrational dose and a defined primary endpoint materially de-risks development timelines. This operational progress enables potential accelerated approval pathways and a planned 2028 launch, converting R&D value into a sustainable commercial opportunity if results are positive.
Improved Financing FlexibilityThe expanded Hercules facility and relaxed covenants materially extend runway and financing optionality. Access to milestone-linked tranches and interest-only terms reduces near-term liquidity pressure and gives management time to advance registrational programs before large principal repayments are due.
Bears Say
Severe Cash BurnPersistent, growing negative operating and free cash flow indicate the company is consuming substantial cash to fund development. This structural burn forces repeated financing or drawdowns on facilities, increasing dilution or leverage risk and pressuring long-term financial sustainability absent product revenue.
Pre-revenue ModelAs a clinical-stage biotech with no product revenue, Dyne’s fundamental value hinges on successful trials and approvals. This creates binary dependency on clinical outcomes and regulatory success to generate recurring cash flows, maintaining high structural execution and funding risk for 2–6+ months horizons.
Dilution And Capitalization RiskDoubling authorized shares materially increases the company’s ability to issue equity, a likely outcome given sustained cash burn and pre-revenue status. Combined with pledged assets under the expanded debt facility, this structurally raises dilution and governance risk for existing shareholders over the medium term.
Dyne Therapeutics News
DYN FAQ
What was Dyne Therapeutics, Inc.’s price range in the past 12 months?
Dyne Therapeutics, Inc. lowest stock price was $8.06 and its highest was $25.00 in the past 12 months.
What is Dyne Therapeutics, Inc.’s market cap?
Dyne Therapeutics, Inc.’s market cap is $3.46B.
When is Dyne Therapeutics, Inc.’s upcoming earnings report date?
Dyne Therapeutics, Inc.’s upcoming earnings report date is Jul 30, 2026 which is in 31 days.
How were Dyne Therapeutics, Inc.’s earnings last quarter?
Dyne Therapeutics, Inc. released its earnings results on May 11, 2026. The company reported -$0.73 earnings per share for the quarter, beating the consensus estimate of -$0.772 by $0.042.
Is Dyne Therapeutics, Inc. overvalued?
According to Wall Street analysts Dyne Therapeutics, Inc.’s price is currently Undervalued.
Does Dyne Therapeutics, Inc. pay dividends?
Dyne Therapeutics, Inc. does not currently pay dividends.
What is Dyne Therapeutics, Inc.’s EPS estimate?
Dyne Therapeutics, Inc.’s EPS estimate is -0.75.
How many shares outstanding does Dyne Therapeutics, Inc. have?
Dyne Therapeutics, Inc. has 165,313,800 shares outstanding.
What happened to Dyne Therapeutics, Inc.’s price movement after its last earnings report?
Dyne Therapeutics, Inc. reported an EPS of -$0.73 in its last earnings report, beating expectations of -$0.772. Following the earnings report the stock price went up 4.827%.
Which hedge fund is a major shareholder of Dyne Therapeutics, Inc.?
Currently, no hedge funds are holding shares in DYN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Dyne Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$39.00 (91.08% Upside)
$39.00 (91.08% Upside)
Blogger Sentiment
Bullish
DYN Sentiment 80%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 1.4M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $142.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.2%
Last 30 Days ▲ 1.6%
Last 30 Days ▲ 1.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
108.35%
12-Months-Change
Fundamentals
Return on Equity
-58.28%
Trailing 12-Months
Asset Growth
49.77%
Trailing 12-Months
Company Description
Dyne Therapeutics, Inc.
Dyne Therapeutics, Inc. is a U.S.-based biotechnology firm focused on developing advanced treatments for genetically driven muscle disorders. Utilizing its proprietary FORCE platform, which is engineered to deliver disease-modifying therapeutics, the company is actively engaged in various programs. These initiatives target conditions such as myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral dystrophy, in addition to other rare skeletal, cardiac, and metabolic muscle diseases. The company was founded in 2017 and maintains its corporate headquarters in Waltham, Massachusetts.
DYN Stock 12 Month Forecast
Average Price Target
$39.00
▲(91.08% Upside)
Technical Analysis
Sarepta Therapeutics
―
Cogent Biosciences
―
Arcutis Biotherapeutics
―
Beam Therapeutics
―
Immunocore Holdings
―
Ownership Overview
3.90% Insiders
24.20% Mutual Funds
9.89% Other Institutional Investors
47.98% Public Companies and
Individual Investors